001     277887
005     20240229162350.0
024 7 _ |a 10.20517/2394-4722.2022.32
|2 doi
024 7 _ |a altmetric:142728368
|2 altmetric
037 _ _ |a DKFZ-2023-01554
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Keshwani, Karimali
|0 P:(DE-HGF)0
|b 0
245 _ _ |a Radical skeletal metastatic site irradiation in high-risk neuroblastoma: systematic review and proposal for a randomised trial
260 _ _ |a Mumbai
|c 2023
|b Medknow
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1690877266_20940
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Aim: Neuroblastoma has a variable outcome depending on age, stage, and molecular pathology. Distant metastatic disease is the central feature of high-risk disease. Recommendations for irradiating persistent metastatic deposits with curative intent after systemic therapy vary. It is unclear to what extent this practice may improve local control or survival. This study systematically reviewed the evidence for skeletal metastatic site irradiation and made evidence-based recommendations for clinical practice. Methods: We systematically reviewed the literature on radical radiotherapy of persistent metastases after chemotherapy. The aim was to determine whether a position could be taken regarding metastatic site irradiation in combined modality treatment protocols aiming for a cure and whether recommendations could be formulated Results: The initial search yielded 445 results. After the title and abstract review, 13 full papers were retrieved. Ten papers were found suitable for data extraction. One additional paper was identified. All 11 were graded as Centre for Evidence-Based Medicine Step 4 in quality; there was no high-level evidence. There are suggestions of benefit for skeletal site irradiation in high-risk neuroblastoma; however, there is no certainty, and it was not possible to recommend a particular treatment policy. Conclusion: We recommend that consideration is given to a randomised evaluation of the benefits of radiotherapy to a limited number of residual post-induction-chemotherapy metastatic sites in good responders. This practice could be incorporated as an amendment to existing trials.
536 _ _ |a 899 - ohne Topic (POF4-899)
|0 G:(DE-HGF)POF4-899
|c POF4-899
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef
700 1 _ |a Boterberg, Tom
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Dieckmann, Karin
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Janssens, Geert O.
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Laprie, Anne
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Timmermann, Beate
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Gaze, Mark N.
|0 P:(DE-HGF)0
|b 6
773 _ _ |a 10.20517/2394-4722.2022.32
|0 PERI:(DE-600)2819994-7
|p A27
|t Journal of Cancer Metastasis and Treatment
|v 9
|y 2023
|x 2394-4722
909 C O |o oai:inrepo02.dkfz.de:277887
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-HGF)0
913 1 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 0
914 1 _ |y 2023
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-08-19
915 _ _ |a WoS
|0 StatID:(DE-HGF)0112
|2 StatID
|b Emerging Sources Citation Index
|d 2023-08-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-19
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J CANCER METAS TREAT : 2022
|d 2023-08-19
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-08-19
920 1 _ |0 I:(DE-He78)ED01-20160331
|k ED01
|l DKTK Koordinierungsstelle Essen/Düsseldorf
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)ED01-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21